BioWorld

June 1, 2004

Avastin, Erbitux Pace Up In Colorectal Market Race

Avigen Stops Coagulin-B Phase I, Plans Drug's Future With Bayer

Expanded Access For Genasense Stopped; Partners Behind Drug

Holiday notice

BioWorld Today's offices are closed Monday, May 31, in observance of Memorial Day. No issue will published that day. Read More

Indevus' Sanctura Gets FDA Nod For Overactive Bladder

Breathing a sigh of satisfaction after years of hard work, officials at Indevus Pharmaceuticals Inc. reached a long-awaited milestone on Friday with the FDA approval of Sanctura. (BioWorld Today) Read More

More Of The Same: Alnylam Gets IPO Done, Below Range

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...